DGAP-Media / 16.06.2021 / 06:30 PRESS RELEASE Zurich, Kleinostheim,Xlife Sciences AG (XLS DE): curasan AG and Xlife Sciences AG cooperate in the field of regenerative medicine curasan AG, a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery, and Xlife Sciences AG have initiated a collabo [ … ]

PRESS RELEASEXlife Sciences AG (XLS): Portfolio project listed on the Stock Exchange Vitruvia Medical AG is listed on the Munich Stock Exchange since yesterday The shares of Vitruvia Medical AG are open for trading since yesterday on the Stock exchange in Munich. Vitruvia is based in Germany and Switzerland and develops circulatory systems for hig [ … ]

Capial increase of Xlife Sciences AG Successful capital raising of six million Swiss francs Xlife Sciences AG has successfully closed its capital increase and raised a total of 6.02 million Swiss Francs of new capital as of December 3, 2020. The placement was oversubscribed at the end of the subscription period. The management of the company sees  [ … ]

Xlife Sciences AG: Xlife Sciences expands its project portfolio Two new project companies offer strong synergy potentialXlife Sciences expands its project portfolio to 23 projects by adding Panmabs GmbH and Xarma Life Science GmbH, both based in Mainz. According to the management of Xlife Sciences this creates significant synergies between variou [ … ]

Xlife Sciences AG: M.M. Warburg sets price target to EUR 55.75 In their recently published report, the analysts of Deutsche Bankhaus M.M. Warburg set the price target for the shares of the Swiss management company, Xlife Sciences AG (Xetra: XLS) to EUR 55.75. The company's earnings for the financial year 2020 are expected at 10.4 million euros and  [ … ]